Dupixent is a novel monoclonal antibody that inhibits signaling of interleukin-4 and interleukin-13, key T-helper cell 2 cytokines involved in the inflammatory process. The therapy is supplied in pre-filled syringes for self-administration by subcutaneous injection. Dupixent is the first FDA-approved biologic therapy for atopic dermatitis (AD). The FDA approved Dupixent in March 2017 for the treatment of a subset of adult patients with moderate-to-severe AD that is not well controlled with topical prescription therapies or who cannot use topical therapies. Dupixent is not indicated for first-line use or to treat children.

If you have a Hayes login, click here to view the full report on the Knowledge Center.